There’s gene therapy — change the DNA permanently. There’s gene silencing — shut down production. And then there’s what AIRNA is doing — editing the RNA to fix the mutation while leaving the genome completely untouched. It’s the Goldilocks approach to genetic medicine, and it just hit the clinic.

AIR-001 is now in a Phase 1 trial for alpha-1 antitrypsin deficiency (AATD), a genetic disorder where a single mutation in the SERPINA1 gene causes both progressive lung disease and liver damage. Most current treatments only address the lung side — IV augmentation therapy that replaces the missing protein without touching the underlying cause. AIR-001 aims to correct the PiZ mutation at the RNA level, restoring production of functional wild-type protein. Both lungs and liver. One mechanism.

The science here is elegant. AIRNA’s RESTORE+ platform recruits the body’s own ADAR enzymes — proteins that naturally edit RNA — and redirects them to fix the disease-causing mutation. No viral vectors. No permanent genome changes. Just a guide RNA delivered subcutaneously via GalNAc conjugation that tells ADAR exactly where to go. Preclinical data showed greater than 90% editing in primary hepatocytes in vitro and over 50% editing in vivo, with wild-type protein levels restored above the therapeutic threshold.

The money tells the story of momentum: $30 million seed in 2023 (ARCH Venture Partners), $60 million Series A in 2024, and an oversubscribed $155 million Series B last year led by Venrock Healthcare and Forbion Growth. That’s $245 million in under three years for a company that just now dosed its first patient. The investor list reads like a who’s-who of precision medicine — ARCH, Venrock, RTW, Nextech, Forbion.

The Phase 1 is global from day one — approximately 20 sites across 11 countries — which is aggressive for a first-in-human study and suggests AIRNA is already building toward registrational speed. Add in the FDA Orphan Drug Designation, and this has the early markings of a program that wants to move fast through a well-defined rare disease population. RNA editing is no longer theoretical. It’s dosing patients.